SFEIES24 Poster Presentations Diabetes & Metabolism (68 abstracts)
1Mater Misericordiae University Hospital, Dublin, Ireland; 2St Vincents University Hospital, Dublin, Ireland; 3Department of Diabetes, School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences and Medicine, Kings College London, London, United Kingdom; 4The Australian Centre for Behavioural Research in Diabetes, Diabetes Victoria, Melbourne, Australia; 5Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, Netherlands; 6CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands; 7Department of Endocrinology and Nephrology, Copenhagen University Hospital North Zealand, Hillerød, Denmark; 8Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; 9Systems Medicine, School of Medicine, University of Dundee, Dundee, United Kingdom; 10Department of Endocrinology and Diabetes, Montpellier University Hospital, Montpellier, France; 11Institute of Functional Genomics, University of Montpellier, CNRS, INSERM, Montpellier, France; 12Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, United Kingdom; 13Welcome-MRC Institute of Metabolic Science and Department of Medicine, University of Cambridge, Cambridge, United Kingdom; 14Medical University of Graz, Division of Endocrinology & Diabetology, Graz, Austria; 15Department of Psychology, University of Southern Denmark, Odense, Denmark; 16Steno Diabetes Center Odense (SDCO), Odense, Denmark; 17Diabetes Research Centre, University of Leicester, Leicester, United Kingdom
Background: Impaired awareness of hypoglycaemia (IAH) is associated with impaired psychological health in people living with type 1 diabetes (T1D). We explored the differences in anxiety, depression and diabetes distress according to hypoglycaemia awareness in people living with insulin-treated type 2 diabetes (T2D).
Methods: This analysis included 321 T2D participants from the Hypo-METRICS study. Participants completed the General Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9) and Problem Areas In Diabetes (PAID) questionnaires at the baseline visit. IAH was defined as GOLD score >4. Chi-squared and MannWhitney U tests were used to examine between-group differences.
Results: 27% of participants had IAH. For those with IAH vs intact hypoglycaemia awareness (NAH), median [IQR] age was 61[52-66] vs 64[56-70] years (p-value=0.02), 61% vs 65% were men (p-value=0.7), 43% vs 40% were using routine continuous glucose monitoring (p-value=0.8) and median HbA1c was 7.5% [6.8-8.5] vs 7.4% [6.8-8.2] (p-value=0.6). Participants with IAH had higher anxiety (GAD-7: 5 [2-7.5] vs 2.5 [0-6], p-value= 0.004) and depression scores (PHQ-9: 6 [3-10] vs 4 [2-8], p-value=0.017). There were no significant differences in diabetes distress scores (PAID: 20 [9-40] vs 19 [9-36], p-value=0.5).
Conclusion: IAH in people with insulin-treated T2D is associated with higher scores of generalised anxiety and depression, as in IAH in people with T1D, but not diabetes-specific distress. While there may be confounding factors, people with T2D and IAH could be at higher risk of anxiety and depression. It is therefore important to clinically assess psychological health outcomes.